Considering the significance of Braf inhibitors in melanoma treatment, several studies have attempted to decipher the mechanisms for resistance and suggested both mitogen activated protein kinase (MAP kinase) dependent and independent pathways as reasons for vemurafenib resistance[6]. Here, WNK2 is linked to melanoma.